罗欣药业连亏三年 2020年借壳东音股份为中泰证券项目

Core Viewpoint - Luoxin Pharmaceuticals (002793.SZ) reported a revenue of 2.647 billion yuan for the fiscal year 2024, marking an 11.99% increase year-on-year, but the net profit attributable to shareholders was a loss of 962.49 million yuan, which is a 45.58% increase in loss compared to the previous year [1][3]. Financial Performance Summary - Total operating revenue for 2024 was 2,647.37 million yuan, up from 2,363.87 million yuan in the previous year, reflecting an increase of 11.99% [3]. - Operating profit for 2024 was -954.38 million yuan, compared to -586.48 million yuan in the previous year, indicating a decline of 62.73% [3]. - Total profit for 2024 was -948.66 million yuan, a decrease of 57.03% from -604.11 million yuan in the previous year [3]. - The net profit attributable to shareholders for 2024 was -962.49 million yuan, worsening from -661.14 million yuan in the previous year, which is a 45.58% increase in loss [3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -771.15 million yuan, compared to -638.85 million yuan in the previous year, reflecting a 20.71% increase in loss [3]. Historical Performance - Luoxin Pharmaceuticals has reported losses for three consecutive years. In 2022, the operating revenue was 3.588 billion yuan, and the net profit attributable to shareholders was -1.225 billion yuan. In 2023, the operating revenue dropped to 2.364 billion yuan, with a net profit of -661 million yuan [3][4].